Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25428538 | 1.00 | BRD4 (0.36) | BRD4EGLN2PDK1PDK2GRM5 | |
| SCHEMBL26026395 | 0.84 | GPR119 (0.40) | EGLN2SSTR4 | |
| SCHEMBL23326979 | 0.81 | P2RX7 (0.33) | GRM5P2RX7 | |
| SCHEMBL25429344 | 0.80 | ABHD6 (0.41) | — | |
| SCHEMBL25431503 | 0.80 | ABHD6 (0.41) | — | |
| SCHEMBL25428247 | 0.80 | OPRM1 (0.31) | PDK1PDK2 | |
| SCHEMBL25428241 | 0.80 | OPRM1 (0.31) | PDK1PDK2 | |
| SCHEMBL25427523 | 0.76 | ROCK1 (0.35) | — | |
| SCHEMBL25427529 | 0.76 | ROCK1 (0.35) | — | |
| SCHEMBL23327016 | 0.73 | ELANE (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |